Swiss Medical Group (SMG) has acquired CoreMedica Europe for an undisclosed amount to expand its footprint in Europe and the rest of the world.
Switzerland-based CoreMedica Europe specialises in a mass spectrometry technology platform, which identifies a patient’s nutritional profile, using dried blood.
The company also focus on the analysis of a range of biomarkers and offers personalised recommendations, using patented technology in areas such as immunity, nutrition, sports and anti-aging.
Recently, CoreMedica Europe combined Covid-19 screening test and immunity profile with its available home self-collection kit to enable customers to collect their blood at home for coronavirus diagnosis.
As part of the deal, SMG took charge of CoreMedica Europe’s operations in Geneva. This includes the team and the authorisations, and all associated patents, algorithms and other intellectual property held by CoreMedica Europe.
Additionally, SMG negotiated an exclusive distribution agreement in North America with CoreMedica Laboratories, a CAP-accredited and CLIA-certified laboratory based in the US.
Swiss Medical Group chairman and CEO and CoreMedica Europe chairman Francois Marland said: “The objective of SMG is to integrate CoreMedica Europe’s unique expertise in the field of blood tests and personalised recommendations into the network of anti-ageing clinics that SMG is developing in Europe, so as to improve P4 models in the field of anti-ageing and foster preventative care, thereby reducing the costs of treatments.”
SMG invests in the development of companies and clinics in the health sector. It has already established its presence in the European market with age-management clinics in France, Italy and Greece.
The company is currently developing eight new clinics in Germany and plans to open 52 age-management clinics in Europe by 2025.